Several studies demonstrated an increase in TLR4 expression on the cell membrane of RA cells that contributes to the pathogenesis of RA through the MDY88/TRAF6/IRAK pathway, suggesting the TLR4 pathway as a therapeutic target to attenuate the progression of RA. Here, IRAK1 is linked to rheumatoid arthritis.